HOME >> BIOLOGY >> NEWS
Smallpox outbreak: How long would it take for vaccines to protect people? Would it work?

ST. LOUIS -- In the event of a smallpox outbreak in the United States, how long would it take for a vaccinSLU scientist leads national studye to start protecting Americans by stimulating an immune response?

A new national study led by Saint Louis University School of Medicine will attempt to answer this question.

General routine vaccinations for smallpox were stopped in the United States in 1971, and the world was declared free of smallpox in 1980. But because of the recent concern about biowarfare and bioterrorism throughout the world, the U.S. government is making efforts to improve its ability to protect its citizens in the event of a bioterrorist attack involving the smallpox virus (Variola major virus).

This study at Saint Louis University will look at the ability of an investigational vaccine made by Bavarian Nordic to stimulate the immune system against smallpox.

"Vaccines prevent disease by giving the body a jump-start at recognizing the infecting virus or bacteria," said Sharon Frey, M.D., the principal investigator for the study at Saint Louis University. "After successful vaccination, the body experiences a quicker fighting response to the infection, which lessens or completely avoids the symptoms of illness."

Unlike some other diseases, getting vaccinated following exposure to smallpox could provide protective effects. For example, for the flu vaccine to work, people need to get vaccinated before being exposed to influenza. The currently licensed smallpox vaccine, however, provides benefits post-exposure, and may be useful in further preventing the spread of the disease.

"If there were a release of the smallpox virus, we would vaccinate people immediately after the release," Frey said. "We'd move in and vaccinate people to prevent the spread."

Frey said this research compares the ability of a new investigational smallpox vaccine called IMVAMUNE to produce a strong immune response
'"/>

Contact: Joe Muehlenkamp
muehlenk@slu.edu
314-977-8015
Saint Louis University
30-Apr-2007


Page: 1 2

Related biology news :

1. AAAS analysis finds Congress would add billions to FY 2008 R&D investment
2. The bee that would be queen
3. 2-protein team would be lost without each other
4. Healthy coastal wetlands would adapt to rising oceans
5. Is it ethical for scientists to do research abroad that would be forbidden at home?
6. Designer babies - what would you do for a healthy baby?
7. New discovery: If it werent for this enzyme, decomposing pesticide would take millennia
8. Proposal would allow wild animals to roam North America
9. Cookbook recipes would cure disease with nontoxic DNA delivery systems
10. Passage of Marin County GMO ban would encourage widespread use of harsh pesticides
11. Passage of GMO ban in San Luis Obispo would encourage use of harsh pesticides

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... and HAMILTON, Bermuda , Feb. ... ADXS ) and SELLAS Life ... on developing cancer immunotherapies, today announced that Advaxis ... novel cancer immunotherapy agent using Advaxis, proprietary ... WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S). ...
(Date:2/25/2017)... (PRWEB) , ... February 25, 2017 , ... ... Verified Clinical Trials in an ongoing effort to create meaningful change ... advocacy, and pharmaceutical research with emphasis on consumers and patients’ mental health well-being. ...
(Date:2/24/2017)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... and CEO, Jim Joyce . In ... Saturday, Bill Gates warned world leaders that ... nuclear weapons. Mr. Gates expressed his concern, which is ... scientific terrorists have access to the necessary tools to ...
(Date:2/24/2017)... 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ("China ... company in China, today announced its financial results for the ... Fourth Quarter 2016 Financial Highlights Total ... in RMB terms, or increased by 13.6% in USD terms ... of 2015. Gross profit increased by 13.3% ...
Breaking Biology Technology:
Cached News: